GERN · Geron Corp
United States · RS rating 18 · As of 2026-10-14
| Price | 1.19 USD |
|---|---|
| 1-day change | -0.8% |
| RS rating (overall / 1M / 3M / 12M) | 18 / 25 / 23 / 36 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 18 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +1.7% |
| Distance from 52-week high | +39.0% |
| Market cap (USD) | $961.4M |